CA-GLOBALITY
Globality , the leading AI-powered digital solution for sourcing services, and Allegis Global Solutions (AGS), the leading provider of global workforce solutions, today announced a partnership that transforms services procurement management so organizations can realize the maximum value from their services spend.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005144/en/
By closing the loop between sourcing and spend management, the partnership will deliver increased value through the end-to-end procurement process, incorporating AI-powered insights every step of the way. As a result, AGS customers will benefit from real-time data and intelligence on supplier performance in Globality’s self-serve Platform, leading to better buying decisions.
“Today’s workforce is dramatically different than it was a year ago, with global enterprises more dependent than ever on external suppliers for their consulting, marketing, IT, HR, legal and other service needs for agility and adaptability,” said Globality Chief Revenue Officer Keith Hausmann. “Without the right technology, processes and information in place, businesses historically will spend 10% to 30% more on outside services. Completing the source-to-pay process with this new integration ensures AGS customers have greater insights for all their high-value services, resulting in more efficient procurement decisions, faster speed to market and better supplier quality.”
Delivering a path to improved management of services spend, the partnership provides multiple advantages:
- Faster engagement: Increasing efficiencies and accelerating speed to market by automating procurement processes with AI-powered, self-serve sourcing
- Better supplier quality: Revealing the best-performing suppliers using data-enabled intelligence to facilitate continuous machine learning
- Increased user satisfaction: Boosting adoption of the overall procurement strategy and enhancing compliance through a consumer-like, intuitive sourcing experience
- Strategic transformation: Enabling better buying decisions with more compliant supplier engagement, competitively sourced spend and greater insights into what is delivered after the contract is signed
- End-to-end value realization: Identifying optimal solutions at the best available cost and incorporating feedback that makes future sourcing activity on the Platform even more robust and intelligent
With strategic sourcing increasingly viewed as a critical source of transformational innovation for global enterprises, companies are actively seeking ways to improve their bottom line and increase efficiency gains. Globality’s Platform transforms the sourcing of high-value services by automating the demand creation, supplier identification, proposal evaluation and statement of work (SOW) creation process with an intuitive self-serve experience. Companies can dynamically source the best-fit supplier for every complex service, while AGS manages delivery, generating actionable, real-time insights and identifying opportunities for additional savings.
“From opportunity to RFP, selection, management and performance tracking, an AGS and Globality solution closes the loop on strategy and execution to deliver a continuous cycle of performance improvement and an improved end-user experience,” said AGS Head of Procurement Solutions Strategy Jon Kesman. “This end-to-end solution ensures companies only contract for what they need and no longer leave significant dollars on the table with services being poorly sourced or left unmanaged after the contract is signed.”
“The AGS and Globality solution gives users faster engagement by modernizing and simplifying what can be a cumbersome RFP process when it comes to services and ensuring better supplier quality through continuous AI-driven learning, which increases end-user satisfaction and enhances compliance in the procurement process with its easy-to-use interface,” Kesman added.
To learn more about the partnership or schedule a demo, visit https://learn.allegisglobalsolutions.com/en-us/globality .
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to revolutionize how companies buy and sell services. Through its AI-powered Platform and marketplace, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding five years ago to $310 million. For more information, visit Globality’s website at www.globality.com .
About Allegis Global Solutions
Allegis Global Solutions (AGS) is the leading provider of workforce solutions. AGS transforms the way the world acquires talent in order to deliver immediate and lasting impact. Through decades of industry experience, and with services across 60+ countries, AGS knows what it takes to innovate, consult, design and implement successful, creative and data-driven talent solutions across all workforce categories. Learn more at www.allegisglobalsolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
